SCIENTIFIC LETTER

Cardiac abnormalities in patients with Leber's hereditary optic neuropathy

P Sorajja, M G Sweeney, R Chalmers, B Sachdev, P Syrris, M Hanna, N D Wood, W J McKenna, P M Elliott

Heart 2003;89:791-792

Leber's hereditary optic neuropathy (LHON) is characterised by acute or subacute central visual loss¹ that typically occurs in early adult life. Three mitochondrial DNA (mtDNA) point mutations, 3460, 11778, and 14484, account for more than 90% of all LHON cases.² Cardiac involvement in LHON has been suspected ever since Leber's original 1871 report in which some patients with the disease complained of palpitations. The aim of this study was to determine the prevalence and nature of cardiac abnormalities in patients with LHON by systematically evaluating cardiac structure and function using echocardiography and adenosine testing.

METHODS

The study population comprised 24 consecutive patients with LHON diagnosed at Queen Square Hospital, London. The diagnosis of LHON was based on characteristic clinical features of the disease and/or the presence of a primary LHON mutation.³ Cardiovascular examination and investigation were performed at St George's Hospital, London. The investigation was approved by the local research ethics committee. All patients provided written informed consent before participation in the study.

Each patient underwent an initial clinical assessment and 12 lead ECG. ECG evidence of left ventricular hypertrophy was defined in accordance with Romhilt-Estes criteria. Ventricular pre-excitation was defined as a PR interval < 120 ms, QRS duration > 120 ms, and slurred onset of the QRS complex (δ wave). Ten patients gave informed written consent to undergo provocation testing with intravenous adenosine. During continuous ECG monitoring of leads II, aVF, V1, V4, V5, and V6, adenosine was administered via the right antecubital vein in 6 mg increments at 2-3 minute intervals. Administration was repeated until atrioventricular block or pre-excitation occurred. Left ventricular hypertrophy was defined as a left ventricular wall thickness of 15 mm or greater on two dimensional echocardiography. The peak instantaneous left ventricular outflow tract gradient was calculated using continuous wave Doppler and modified Bernoulli equation.

RESULTS

Eleven patients from the same family carried the 3460 mtDNA mutation (table 1). Eight patients, including two siblings, carried the 11778 mtDNA mutation. The remaining five patients,

Table 1 Clinical characteristics and study results for patients harbouring the 3460, 114480, and 11778 mtDNA mutations

Patient	Age/ sex	MtDNA mutation	Cardiac symptoms	Echocardiography				PAT	ECG		
				LA (mm)	EDD (mm)	ESD (mm)	MLVWT (mm)		TWI	L VH	ST abnl
1	62/F	3460	-	36	46	22	16	ASH	+	+	+
2	53/M	3460	-	42	35	22	28	CON	+	+	+
3	53/M	3460	Syncope, angina, dyspnoea	39	30	19	26	CON	+	+	+
4	58/F	3460	Syncope, angina, dyspnoea, palpitations	38	36	23	15	CON	+	+	+
5	38/M	3460	Dyspnoea, palpitations	25	53	32	17	DIS	+	+	+
6	36/F	3460	-	31	42	24	10	-	+	-	+
7	33/F	3460	-	30	46	30	9	-	-	-	-
8	24/M	3460	-	38	48	29	11	-	-	-	-
9	31/M	3460	-	38	47	39	10	-	-	-	-
10	34/F	3460	-	31	44	29	10	-	-	-	+
11	32/M	3460	-	39	50	32	11	-	-	-	+
12	42/M	11778	Dyspnoea, palpitations	34	48	27	12	-	-	+	+
13	44/M	11778	Post-micturition syncope	27	47	29	11	-	+	+	+
14	54/M	11778	Post-micturition syncope	38	48	30	11	-	-	+	-
15	27/M	11778	-	32	47	29	10	-	-	-	-
16	48/F	11778	Palpitations	21	44	25	10	-	-	-	-
17	57/M	11778	-	36	46	26	10	-	-	-	-
18	42/M	11778	-	34	51	29	10	-	+	-	+
19	32/F	11778	-	30	45	29	9	-	+	-	-
20	51/M	14484	Palpitations	40	59	36	10	-	-	+	+
21	63/M	14484	-	33	46	21	10	-	-	-	-
22	56/M	14484	-	42	45	30	9	-	-	-	-
23	40/M	14484	Nil	37	45	25	12	-	-	-	-
24	67/M	14484	Nil	30	45	26	7	-	-	-	-

ASH, asymmetrical septal hypertrophy; CON, concentric hypertrophy; LVH, left ventricular hypertrophy; DI, distal hypertrophy; EDD, end diastolic diameter; ESD, end systolic diameter; MLVWT, maximal left ventricular wall thickness; LA, left atrium; PAT, pattern of left ventricular hypertrophy; ST abnl, ST segment abnormality; TWI, T wave inversion.

including two siblings, were affected with the 14484 mtDNA mutation.

Three 3460 patients, four 11778 patients, and one 14484 patient had cardiac symptoms. Eight 3460 patients, five 11778 patients, and one 14484 patient had ECG abnormalities. Of the 11 patients with the 3460 mutation, five had myocardial hypertrophy (mean (SD) maximal wall thickness 20 (6) mm, range 16–28 mm). Myocardial hypertrophy was absent in patients with the 11778 and 14484 mutation. Unexplained left ventricular dilatation (end diastolic dimension 59 mm) was seen in one patient with the 14484 mutation. A history of sudden death was recorded in one member (in his 50s) of the family with the 3460 mutation. One patient, with a diagnosis of hypertrophic cardiomyopathy before this study, received a DDD pacemaker for sinus node dysfunction. No patient had evidence of ventricular pre-excitation at rest, or following adenosine provocation. There was no evidence of a skeletal myopathy in any of the patients studied.

DISCUSSION

To the best of our knowledge, this study is the first report describing hypertrophic cardiomyopathy in patients with LHON. The pattern of cardiac hypertrophy was heterogeneous: three patients had concentric hypertrophy, one had asymmetric septal hypertrophy, and one had distal hypertrophy. Cardiac symptoms and isolated ECG abnormalities were also common, but in contrast to previous studies,⁴ we were unable to demonstrate any evidence for ventricular pre-excitation. This may have been because of the small number of patients examined; however, other recent studies have also failed to demonstrate pre-excitation in patients with LHON.³

The fact that hypertrophic cardiomyopathy was observed in a single family of LHON patients with the 3460 mtDNA mutation could be explained by the co-inheritance of familial hypertrophic cardiomyopathy. Extensive screening for sarcomeric protein gene mutations that cause familial hypertrophic cardiomyopathy would be necessary to exclude this possibility, but several observations suggest that the cardiomyopathy was secondary to the 3460 mtDNA mutation; specifically the association between cardiomyopathy and other mitochondrial disorders, the presence of minor cardiac abnormalities in previous studies of patients with LHON, and the presence of 100% co-segregation of the 3460 mutation and cardiac disease.

The 3460, 11778, and 14484 mutations all alter the encoding of complex I, one of the five major protein complexes that make up the mitochondrial oxidative phosphorylation system. Complex I consists of over 40 protein subunits, seven of which (ND1-6, and ND4L) are encoded by mtDNA. The mtDNA encoded subunits are mainly intramembranous and are involved in interactions with ubiquinone and hydrogen ion transfer. The phenotypic heterogeneity with respect to cardiac involvement observed in this study may be explained in part by the different protein subunits that are affected by the 3460, 11778, and 14484 LHON mutations. The 3460 mutation occurs within the gene that encodes the ND1 protein subunit, causing the substitution of hydrophobic alanine for hydrophilic threonine in the NH₂ terminus of the polypeptide, which is rich in other hydrophobic residues. This mutation leads to a reduction in complex I dependent electron transfer activity and a 30–35% decrease in ATP synthesis. In contrast, the 11778 mutation which results in the substitution of histidine for arginine in the ND4 subunit does not appear to compromise electron transfer within the complex itself, but may disrupt interactions between the complex and NADH linked substrates. The 14484 mutation leads to the substitution of

valine for methionine in a poorly conserved region of the gene which codes for the ND6 subunit. Although the pathogenic basis of the 14484 mutation has not been studied extensively, reductions in complex I activity and ATP synthesis have been reported. In the future a greater understanding of the genotype–phenotype relation in this condition may be obtained from assessment of the degree of mtDNA heteroplasmy in the myocardium.

The findings in this study suggest that patients with LHON should routinely undergo cardiac evaluation with echocardiography and ECG. The relation between individual mutations and cardiac disease, and the natural history of cardiac disease in LHON, warrant further study.

Authors' affiliations

*P Sorajja, B Sachdev, W J McKenna, P M Elliott, Department of Cardiological Sciences, St George's Hospital Medical School, London, UK

M G Sweeney, R Chalmers, M Hanna, N D Wood, Institute of Neurology, The National Hospital for Neurology and Neurosurgery, London, UK

P Syrris, Department of Medical Genetics, St George's Hospital Medical School

*Also Mayo Clinic, Rochester, Minnesota, USA

Correspondence to: Dr P M Elliott, Department of Cardiological Sciences, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK; pelliott@sghms.ac.uk

Accepted 9 January 2003

REFERENCES

- 1 Newman NJ. Leber's hereditary optic neuropathy. *Ophthalmol Clin North Am* 1991;4:431.
- 2 Wallace DC, Lott, Brown MD, et al. Report of the committee on human mitochondrial DNA. In: Cuticchia AJ, Pearson PL, eds. *Human gene mapping: a compendium*. Baltimore: Johns Hopkins University Press; 1995:910–54.
- 3 Nikoskelainen E, Wanne O, Dahl M. Pre-excitation syndrome and Leber's hereditary optic neuropathy. *Lancet* 1985;i:696.
- 4 Eva-Riordan P, Harding AE. Leber's hereditary optic neuropathy: the clinical relevance of different mitochondrial DNA mutations. *J Med Genet* 1995;32:81–7.
- 5 Bower SPC, Hawley I, Mackey DA. Cardiac arrhythmia and Leber's hereditary optic neuropathy. *Lancet* 1992;339:1427–8.

Erratum

Schiele TM, et al. Clinical and angiographic acute and follow up results of intracoronary β brachytherapy in saphenous vein bypass grafts: a subgroup analysis of the multicentre European registry of intraluminal coronary β brachytherapy (RENO). *Heart* 2003;89:640–4. Table 2 below was accidentally omitted. The error is regretted.

Table 2 Procedure related parameters per lesion

Debulking	0 (0%)
Use of cutting balloon	10 (14.7%)
Nominal diameter of largest balloon used (mm)	4.03 (3.77)
New stent implanted	22 (32.4%)
Mean (SD) dose at 2 mm (Gy)	20.1 (3.2)
30 mm source train	20 (29.4%)
40 mm source train	47 (69.1%)
60 mm source train	1 (1.5%)
Pullback manoeuvre	17 (25.0%)
Fractionated treatment	4 (5.9%)
Primary success	62 (91.2%)